Los resultados de los ensayos clínicos en fase 3 de la vacuna de Sinopharm, realizados en Emiratos Árabes y Bahrain, fueron publicados en la Revista de la Asociación Médica Estadounidense. La vacuna con la cepa de Beijing tiene una eficacia del 78,1% para reducir el riesgo del COVID-19 sintomático en adultos entre los 18 y 59 años. [Fuente: América TV]
:quality(75)/cdn.jwplayer.com/v2/media/5h1UIiRn/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/s0SU3hoV/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/cAs1Uyyl/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/74dOikgx/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/YUSSR3R3VFAE3MVB55WBZUCA3A.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/Fp4txKkv/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/0Iveihj3/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/WJ7ovIRU/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/JMggmIoe/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/a4PjgZNV/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/zQ1CDAtp/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/NJYRXMWTJNBH7AG5CKMEOLNJ7E.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/FACEUXZLE5DNHFQEAYVP66PHSI.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/5h1UIiRn/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/74dOikgx/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/YUSSR3R3VFAE3MVB55WBZUCA3A.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/75T3paxO/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/cAs1Uyyl/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/TVKBQS3TEJATNJ2O5DPSM6WRRQ.png)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/V2ABWUUBNNAEZJ4FSI64SU5O3U.png)
:quality(75)/cdn.jwplayer.com/v2/media/KBOpcpUE/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/koNs9MA2/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/6bLTGi5d/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/KgeU8b6Q/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/a6mwPQ4X/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/X3PAJUVAAFHRXHUYV5TON7UAAY.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/wXUo9jVU/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/nu9nKgwG/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/GCHGHNUMHVAIDBFA2VHOVRIAMY.png)
:quality(75)/cdn.jwplayer.com/v2/media/c0S03whF/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/azLadx4o/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/FQ5XSTUGQ5DI3DYDC3MUSLQL6A.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/9a1H4G0a/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/Xv8iJGpA/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/EXTCEP2GUBC7XBDWQE34RG4BO4.png)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/DOIUFLVUQ5AJDN2ZVTQQC7KHZ4.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/dXst1BW1/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/JW2JBE7IBZEY5NR2VH4KVTPGZ4.png)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/42WZKDIDGVA6VKQDF75376W2CA.png)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/ENCJ6JEIFZHT5E6UXK3KZ5RCUU.png)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/UZ27WLDNBFBCPCMLG42DQCNJYA.png)